32
BioTOPics 46 | September 2013
BioTOP-Report
Technology Transfer
Dr. Ulla Peters
UHY Deutschland AG Wirtschaftsprüfungsgesellschaft/Zimmerstraße 23/D-10969 Berlin
Phone +49 30 226593-0/Fax +49 30 22679050/www.uhy-deutschland.de/www.uhy.com
Life sciences companies are in safe hands with UHY.
UHY Deutschland AG is a joint venture of long estab-
lished auditing and consulting firms with a total of 250
employees and partners.
As a member of UHY International, a global association
of independent accounting and consulting firms with
over 7,000 employees we can provide audit, account-
ing, tax and consulting services in 270 business centres
across the globe.
UHY Deutschland AG has extensive experience in finan-
cial and consulting services for life sciences companies
for many years. We offer the following services:
p
Audits of financial
and consolidated statements
under the German Commercial Code (HGB) and
IFRS
p
Accounting & Reporting
p
Due diligence (financial and tax) and business
valuations
p
Consulting services on IPOs
p
Business Advisory
p
Mergers & Acquisitions (M&A)
p
German and international taxation
Berlin/Bremen/Cologne/Frankfurt/Hamburg/Munich/Stuttgart
Contact
CoLaborator: An incubator space for start-ups
Alongside many publicly funded initiatives, Bayer HealthCare an-
nounced its concept for a second CoLaborator after San Francisco
at its Berlin location in May 2013. The new CoLaborator of Bayer
HealthCare will be established in direct vicinity to the company’s
own research laboratories and provide suitable premises for rent
for up to ten bioscience start-ups whose ideas, developments
and technology platforms match Bayer’s own research activities.
Internal research at Bayer HealthCare focuses on four core thera-
peutic fields: oncology, cardiology, gynaecology and haematology.
The project will support the young entrepreneurs in establishing
their research labs and, if desired, act as their first contact for
cooperation with industry. The CoLaborator has a building of its
own with an area of app. 800 sqm, of which some 420 sqm are
laboratories.
Prof. Dr. Andreas Busch
Member of the Executive Committee of Bayer
HealthCare and Head of Global Drug Discovery
Cooperation with academic partners and biotech companies is
a key element of Bayer HealthCare’s innovation strategy. We
strongly believe that jointly using the enormous knowledge
inside and outside the company will help us to get a better
understanding of major disease mechanisms and to improve
drug development. The new CoLaborator in Berlin will foster
communication and cooperation with innovative partners in
Berlin.
34
BioTOPics 46 | September 2013
BioTOP-Report
Life Sciences
A Science and Research Hub
Nationally and internationally, Berlin-Brandenburg is regarded as one of the leading life sciences hubs. The
region offers optimal conditions for this field as a TOP life sciences location with five universities, many higher
education facilities and a unique extramural research density. Its most prestigious institutions in biotechnology
and the life sciences include four Max Planck Institutes, four Leibniz Institutes, two Fraunhofer Institutes and
two centres of the Helmholtz Association. In addition, the region is home to a wide range of hospitals, headed
by one of the largest university hospitals in Europe, Charité – Universitätsmedizin Berlin.
From pharmaceutical research, through diagnostics, theranostics
and molecular genetics, to the development of innovative bio-
materials for medical application, scientists from diverse disci-
plines, including medicine, biology, chemistry, nutrition science,
bioinformatics, pharmacology and physics, cooperate closely in
the German capital region. In addition to scientific expertise, Ber-
lin-Brandenburg also offers an excellent infrastructure with its
wide range of networks and transfer platforms which link univer-
sities, research facilities and users. A new dimension in the trans-
fer of insights from basic into clinical research is now provided
by the Berlin Institute of Health (BIH) which was opened in June
2013 and will further enhance the position of the capital region
as a leading centre for translational and systems medicine. You
will find more information in this topic on page 36.
Ideas for biobased products of the future
Biotechnology know-how is finding areas of application with con-
siderable potential beyond the healthcare sector. The develop-
ment and production of biomass-based plastics will be in increas-
ing demand in the future and also offers major opportunities for
the innovation capacity and economic potential of Berlin-Bran-
denburg. Of special importance to this field are the Leibniz In-
APRIL 2012
The Berlin scientist Tatiana Krotkova of Leibniz-Institut für Molekulare Phar-
makologie (FMP) and of NeuroCure cluster of excellence at Charité-Univer-
sitätsmedizin Berlin receives this year's research award for young scientists
from Human Frontier Science Programs (HFSP)
++++
MDC-researcher Prof.
Michael Gotthardt and Prof. Norbert Hübner discover a new mechanism for
myocardial disease in collaboration with colleagues from the USA
++++
A
10.000 Euro research award of the Deutsche Rheumaliga is awarded to the
Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)
MAY 2012
Max-Delbrück-Centrum receives multi-million euro funding for a German-
Israeli doctoral training programme
++++
A common matter of the heart for
140 top scientists: German Centre for Cardiovascular Research
++++
At the
Institute for Biomaterial Science of Helmholtz-Zentrum Geesthacht in Teltow,
a new Helmholtz graduate school for macromolecular bioscience is being set
up
++++
Transatlantic Consortium for Regenerative Medicine founded in Ber-
lin
++++
Charité – Universitätsmedizin Berlin reaches rank 1 of Focus-ranking
"Germany's best hospital"
JUNE 2012
Charité – Universitätsmedizin Berlin attracts another graduate school in the
Excellence Initiative: Berlin School of Integrative Oncology
++++
John-Hop-
kins-University and Fraunhofer Heinrich Hertz Institute sign agreement in
principle to jointly develop medical applications of integrated optical sensors
JULY 2012
1100 years in 100 seconds: The Berlin scientist Leif Schröder at the FMP has
breakthrough with his group in new diagnosis method
++++
Neuronal stem
cells destroy brain tumours – MDC and Charité-scientists elucidate new mech-
anism of action
AUGUST 2012
MDC-scientists Dr. Sandrine Sander and Prof. Klaus Rajewsky of MDC Berlin-
Buch discover new key element in formation of Burkitt lymphoma
++++
Ger-
trud Reemtsma Foundation awards HU-biophysicist Peter Hegemann as co-
founder of optogenetics with the Zülch-Preis 2012
SEPTEMBER 2012
Scientists of Charité – Universitätsmedizin Berlin and Labor Berlin succeed in
deciphering the molecular signature of Hantavirus infection in humans
++++
Graduate school BSRT receives support from the Friede Springer Foundation
OCTOBER 2012
A team of scientists around Anna Flögel of German Institute of Human Nutri-
tion (DifE) and Tobias Pischon of Max-Delbrück-Centrum (MDC) identified
14 new biomarkers for type-II diabetes which can be the foundation of the
development of new ways of therapy and prevention for the metabolic dis-
ease.
++++
The World Health Summit brings top-class participants to Berlin
for the fourth time.